Trial reportFrontiers in immunology2018
Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis.
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Conduct and reporting of formula milk trials: systematic review.BMJ (Clinical research ed.) · 2021Pooled it
- Acid ceramidase overactivity drives ceramide loss, leading to atopic dry skin and Th2-skewed immune polarization.The Journal of pathology · 2026Article
- Chemokine ligand-receptor interactions as potential therapeutic targets for atopic dermatitis: from basic to clinical research.Frontiers in allergy · 2026Review
- The Association between Gut Microbiota and Serum Biomarkers in Children with Atopic Dermatitis.Biomedicines · 2024Article
- The Role of Collagens in Atopic Dermatitis.International journal of molecular sciences · 2024Review
- Systemic inflammatory proteins in offspring following maternal probiotic supplementation for atopic dermatitis prevention.Clinical and molecular allergy : CMA · 2023Article
- Intrinsic Effects of Exposome in Atopic Dermatitis: Genomics, Epigenomics and Regulatory Layers.Journal of clinical medicine · 2023Review
- Atopic Dermatitis: Striving for Reliable Biomarkers.Journal of clinical medicine · 2022Review
- Synbiotic containing extensively hydrolyzed formula improves gastrointestinal and atopic symptom severity, growth, caregiver quality of life, and hospital-related healthcare use in infants with cow's milk allergy.Immunity, inflammation and disease · 2022Article
- Diagnostic Value of a Novel Eosinophil Cationic Protein-Myeloperoxidase Test Paper Before and After Treatment for Allergic Rhinitis.Journal of asthma and allergy · 2022Article
- Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council.The Journal of allergy and clinical immunology · 2021Review
- Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives.Pharmacological reports : PR · 2021Review
- Chemokines during anaphylaxis: the importance of CCL2 and CCL2-dependent chemotactic activity for basophils.Clinical and translational allergy · 2020Article
- Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood.The Journal of allergy and clinical immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in infancy with a complex pathology. In adults, the clinical severity of AD has been associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, including high levels of CC chemokine ligand (CCL) 17 and CCL22 chemokines. Objective: To explore the possible association between serum chemokine levels and AD severity in infants with moderate-to-severe AD and elevated immunoglobulin E (IgE). Subjects and methods: Serum samples ( Results: 31 Infants up to 11 months of age, with an objective-SCORAD score (oSCORAD) ≥ 20 and elevated total-IgE and/or specific-IgE levels were included. In time, the median oSCORAD decreased in both groups by -8 (control, Conclusion: While this study is small and exploratory in nature, these data contribute to immune biomarker profiling and understanding of AD in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.